Chicago’s AbbVie has presented data from the CLL14 trial, examining Venclexta (venetoclax) plus Roche’s CD20 blocker Gazyva (obinutuzumab), as a first-line ther 5 June 2019
Swiss pharma giant Novartis has presented results from the COMBI-d and COMBI-v trials, testing a combination of Tafinlar (dabrafenib) and Mekinist (trametinib), 5 June 2019
Anglo-Swedish pharma major AstraZeneca and US drug giant Merck & Co have presented further evidence in support of Lynparza (olaparib) at the 2019 ASCO meeting. 4 June 2019
Bristol-Myers Squibb has announced updated results from studies evaluating Opdivo (nivolumab) and Yervoy (ipilimumab) at the annual meeting of the American Soci 4 June 2019
Deciding which company has presented the most significant data at an ASCO meeting is often a matter of perspective, but Amgen is definitely a contender at this 3 June 2019
An interim analysis of the Phase III ENZAMET trial has found that 80% of men with metastatic hormone-sensitive prostate cancer who received Xtandi (enzalutamide 3 June 2019
Merck & Co’s industry-leading immuno-oncology drug Keytruda (pembrolizumab) is no stranger to making the headlines at ASCO, and this year’s meeting is no except 3 June 2019
Swiss pharma giant Novartis has released data showing statistically significant overall survival (OS) results for the CDK4/6 inhibitor Kisqali (ribociclib), in 3 June 2019
Positive data at the annual meeting of the American Society of Clinical Oncology (ASCO) will help boost chances for Sanofi’s isatuximab in a looming head-to-hea 3 June 2019
Immunotherapy specialist Atara Biotherapeutics has presented clinical results relating to its biomarker research at the annual meeting of the American Society o 3 June 2019
French drugmaker Ipsen is to present new data on three of its drugs at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting – namely Cabometyx ( 24 May 2019
As industry majors prepare to make a splash at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO), 2003-founded nanomedicine specia 24 May 2019
It’s ASCO time again. The annual meeting of the American Society of Clinical Oncology (ASCO) is now just over a week away, with the event due to start in Chicag 22 May 2019
When it comes to long-term investment in pharma stocks, looking at pipeline assets at a pre-clinical or early clinical stage gives as good a clue as any as to w 17 May 2019
Basel, Switzerland-based pharma giant Novartis has provided an outline of the data it intends to present at the American Society of Clinical Oncology (ASCO) ann 17 May 2019
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.